These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 10850442)

  • 21. Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt.
    Bezzi M; Hasmim M; Bieler G; Dormond O; Rüegg C
    J Biol Chem; 2003 Oct; 278(44):43603-14. PubMed ID: 12933798
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo.
    Fournier PG; Daubiné F; Lundy MW; Rogers MJ; Ebetino FH; Clézardin P
    Cancer Res; 2008 Nov; 68(21):8945-53. PubMed ID: 18974139
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bisphosphonates: preclinical review.
    Green JR
    Oncologist; 2004; 9 Suppl 4():3-13. PubMed ID: 15459425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases.
    Hiraga T; Williams PJ; Mundy GR; Yoneda T
    Cancer Res; 2001 Jun; 61(11):4418-24. PubMed ID: 11389070
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis.
    Daubiné F; Le Gall C; Gasser J; Green J; Clézardin P
    J Natl Cancer Inst; 2007 Feb; 99(4):322-30. PubMed ID: 17312309
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bisphosphonates as anticancer therapy for early breast cancer.
    Mahtani R; Jahanzeb M
    Clin Breast Cancer; 2010 Oct; 10(5):359-66. PubMed ID: 20920980
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.
    Jagdev SP; Coleman RE; Shipman CM; Rostami-H A; Croucher PI
    Br J Cancer; 2001 Apr; 84(8):1126-34. PubMed ID: 11308265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs.
    Michigami T; Hiraga T; Williams PJ; Niewolna M; Nishimura R; Mundy GR; Yoneda T
    Breast Cancer Res Treat; 2002 Oct; 75(3):249-58. PubMed ID: 12353814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New role for an established drug? Bisphosphonates as potential anticancer agents.
    Koul HK; Koul S; Meacham RB
    Prostate Cancer Prostatic Dis; 2012 Jun; 15(2):111-9. PubMed ID: 21876554
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease.
    Dedes PG; Kanakis I; Gialeli Ch; Theocharis AD; Tsegenidis T; Kletsas D; Tzanakakis GN; Karamanos NK
    Biochim Biophys Acta; 2013 Jun; 1830(6):3625-34. PubMed ID: 23395844
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pilot studies of the effect of zoledronic acid (Zometa) on tumor-derived cells ex vivo in the ATP-based tumor chemosensitivity assay.
    Knight LA; Conroy M; Fernando A; Polak M; Kurbacher CM; Cree IA
    Anticancer Drugs; 2005 Oct; 16(9):969-76. PubMed ID: 16162973
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risedronate inhibits human osteosarcoma cell invasion.
    Xin ZF; Kim YK; Jung ST
    J Exp Clin Cancer Res; 2009 Jul; 28(1):105. PubMed ID: 19624845
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The potential role of bisphosphonates as adjuvant therapy in the prevention of bone metastases.
    Paterson AH
    Cancer; 2000 Jun; 88(12 Suppl):3038-46. PubMed ID: 10898349
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of Zoledronic acid in prostate cancer.
    Montague R; Hart CA; George NJ; Ramani VA; Brown MD; Clarke NW
    Eur Urol; 2004 Sep; 46(3):389-401; discussion 401-2. PubMed ID: 15306113
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of bisphosphonates in breast and prostate cancers.
    Brown JE; Neville-Webbe H; Coleman RE
    Endocr Relat Cancer; 2004 Jun; 11(2):207-24. PubMed ID: 15163299
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis.
    Palmieri C; Fullarton JR; Brown J
    Clin Cancer Res; 2013 Dec; 19(24):6863-72. PubMed ID: 24166910
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bisphosphonates for breast cancer.
    Pavlakis N; Schmidt R; Stockler M
    Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of two novel bisphosphonates on bone cells in vitro.
    Evans CE; Braidman IP
    Bone Miner; 1994 Aug; 26(2):95-107. PubMed ID: 7994190
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined effects of zoledronic acid and doxorubicin on breast cancer cell invasion in vitro.
    Woodward JK; Neville-Webbe HL; Coleman RE; Holen I
    Anticancer Drugs; 2005 Sep; 16(8):845-54. PubMed ID: 16096432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Antitumor properties of the bisphosphonate zoledronate and potential therapeutic implications in the clinic].
    Clézardin P
    Bull Cancer; 2010 Aug; 97(8):937-49. PubMed ID: 20595092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.